In late 2015 and early 2016, the first dengue vaccine, Dengvaxia (CYD-TDV) by Sanofi Pasteur, was registered in several countries for use in individuals 9-45 years of age living in endemic areas. The Strategic Advisory Group of Experts (SAGE) on immunization reviewed CYD-TDV in April 2016 and recommended countries consider introduction of the vaccine in geographic settings (national or subnational) with high endemicity.
Other tetravalent live-attenuated vaccines are under development in phase II and phase III clinical trials, and 3 other vaccine candidates (based on subunit, DNA and purified inactivated virus platforms) are at earlier stages of clinical development.
Wow, cool post. I'd like to write like this too - taking time and real hard work to make a great article... but I put things off too much and never seem to get started. Thanks though. dengue fever vaccination
ReplyDelete